{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:33:23Z","timestamp":1795041203835,"version":"4.10.2"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-026-14428-y","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:45:23Z","timestamp":1777045523000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost of illness of type 2 diabetes mellitus with a cardiovascular comorbidity and comparison with guideline recommendations: a German claims data analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Stephan","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Aberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Duerschmied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Grond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lehrke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven-Oliver","family":"Tr\u00f6bs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schultze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Kossack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena Margareta","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Gabler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"14428_CR1","doi-asserted-by":"publisher","first-page":"A336","DOI":"10.1016\/j.jval.2014.08.650","volume":"17","author":"RA Greiner","year":"2014","unstructured":"Greiner RA, Paulus G, Driedger J, Schr\u00f6der C, Timtschenko V, Batscheider A, et al. Epidemiology and unmet medical need in diabetes mellitus type 2 in Germany -Results of a literature search. Value Health. 2014;17:A336. https:\/\/doi.org\/10.1016\/j.jval.2014.08.650.","journal-title":"Value Health"},{"key":"14428_CR2","doi-asserted-by":"publisher","unstructured":"T\u00f6nnies T, Hoyer A, Brinks R, Kuss O, Hering R, Schulz M. Spatio-temporal trends in the incidence of type 2 diabetes in Germany-analysis of the claims data of 63 million persons with statutory health insurance from 2014 to 2019. Deutsches Arzteblatt international. 2023. https:\/\/doi.org\/10.3238\/arztebl.m2022.0405","DOI":"10.3238\/arztebl.m2022.0405"},{"key":"14428_CR3","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/j.amjcard.2017.05.014","volume":"120","author":"M Lehrke","year":"2017","unstructured":"Lehrke M, Marx N. Diabetes mellitus and heart failure. Am J Cardiol. 2017;120:S37\u201347. https:\/\/doi.org\/10.1016\/j.amjcard.2017.05.014.","journal-title":"Am J Cardiol"},{"key":"14428_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017. Cardiovasc Diabetol. 2018;17:83. https:\/\/doi.org\/10.1186\/s12933-018-0728-6.","journal-title":"Cardiovasc Diabetol"},{"key":"14428_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2047487319878371","volume":"26","author":"E Dal Canto","year":"2019","unstructured":"Dal Canto E, Ceriello A, Ryd\u00e9n L, Ferrini M, Hansen TB, Schnell O, et al. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26:25\u201332. https:\/\/doi.org\/10.1177\/2047487319878371.","journal-title":"Eur J Prev Cardiol"},{"key":"14428_CR6","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","volume":"389","author":"C Magnussen","year":"2023","unstructured":"Magnussen C, Ojeda FM, Leong DP, Alegre-Diaz J, Amouyel P, Aviles-Santa L, et al. Global effect of modifiable risk factors on cardiovascular disease and mortality. N Engl J Med. 2023;389:1273\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2206916.","journal-title":"N Engl J Med"},{"key":"14428_CR7","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/dom.14924","volume":"25","author":"T Otto","year":"2023","unstructured":"Otto T, Diesing J, Borchert J, Heitmann E, Schloot C, Lebrec N. Age-dependent prevalence of type 2 diabetes, cardiovascular risk profiles and use of diabetes drugs in Germany using health claims data. Diabetes Obes Metab. 2023;25:767\u201375. https:\/\/doi.org\/10.1111\/dom.14924.","journal-title":"Diabetes Obes Metab"},{"key":"14428_CR8","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/dme.13336","volume":"34","author":"E Jacobs","year":"2017","unstructured":"Jacobs E, Hoyer A, Brinks R, Icks A, Ku\u00df O, Rathmann W. Healthcare costs of Type 2 diabetes in Germany. Diabet Med. 2017;34:855\u201361. https:\/\/doi.org\/10.1111\/dme.13336.","journal-title":"Diabet Med"},{"key":"14428_CR9","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.jval.2017.12.019","volume":"21","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Economic burden of cardiovascular disease in type 2 diabetes: a systematic review. Value Health. 2018;21:881\u201390. https:\/\/doi.org\/10.1016\/j.jval.2017.12.019.","journal-title":"Value Health"},{"key":"14428_CR10","doi-asserted-by":"publisher","first-page":"280","DOI":"10.18553\/jmcp.2018.24.3.280","volume":"24","author":"S Mehta","year":"2018","unstructured":"Mehta S, Ghosh S, Sander S, Kuti E, Mountford WK. Differences in all-cause health care utilization and costs in a type 2 diabetes mellitus population with and without a history of cardiovascular disease. J Manag Care Spec Pharm. 2018;24:280\u201390. https:\/\/doi.org\/10.18553\/jmcp.2018.24.3.280.","journal-title":"J Manag Care Spec Pharm"},{"key":"14428_CR11","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1002\/ehf2.12985","volume":"7","author":"OS Reifsnider","year":"2020","unstructured":"Reifsnider OS, Kansal AR, Franke J, Lee J, George JT, Brueckmann M, et al. Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure. ESC Heart Fail. 2020;7:3910\u20138. https:\/\/doi.org\/10.1002\/ehf2.12985.","journal-title":"ESC Heart Fail"},{"key":"14428_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001313","author":"OS Reifsnider","year":"2021","unstructured":"Reifsnider OS, Kansal AR, Gandhi PK, Cragin L, Brand SB, Pfarr E, et al. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease. BMJ Open Diabetes Res Care. 2021. https:\/\/doi.org\/10.1136\/bmjdrc-2020-001313.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"14428_CR13","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1055\/a-1018-9106","volume":"127","author":"R Landgraf","year":"2019","unstructured":"Landgraf R, Aberle J, Birkenfeld AL, Gallwitz B, Kellerer M, Klein H, et al. Therapy of type 2 diabetes. Exp Clin Endocrinol Diabetes. 2019;127:S73\u201392. https:\/\/doi.org\/10.1055\/a-1018-9106.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"14428_CR14","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1055\/a-1018-9078","volume":"127","author":"A Petersmann","year":"2019","unstructured":"Petersmann A, M\u00fcller-Wieland D, M\u00fcller UA, Landgraf R, Nauck M, Freckmann G, et al. Definition, classification and diagnosis of diabetes mellitus. Exp Clin Endocrinol Diabetes. 2019;127:S1\u20137. https:\/\/doi.org\/10.1055\/a-1018-9078.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"14428_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12913-014-0669-z","volume":"15","author":"SF Oude Wesselink","year":"2015","unstructured":"Oude Wesselink SF, Lingsma HF, Robben PBM, Mackenbach JP. Guideline adherence and health outcomes in diabetes mellitus type 2 patients: a cross-sectional study. BMC Health Serv Res. 2015;15:22. https:\/\/doi.org\/10.1186\/s12913-014-0669-z.","journal-title":"BMC Health Serv Res"},{"key":"14428_CR16","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1007\/s13300-020-00935-6","volume":"11","author":"N Papanas","year":"2020","unstructured":"Papanas N, Elisaf M, Kotsa K, Melidonis A, Bousboulas S, Bargiota A, et al. Adherence to the national guidelines for follow-up protocol in subjects with type 2 diabetes mellitus in greece: the GLANCE study. Diabetes Ther. 2020;11:2887\u2013908. https:\/\/doi.org\/10.1007\/s13300-020-00935-6.","journal-title":"Diabetes Ther"},{"key":"14428_CR17","doi-asserted-by":"publisher","first-page":"e000639","DOI":"10.1136\/bmjdrc-2018-000639","volume":"7","author":"SA Karlsson","year":"2019","unstructured":"Karlsson SA, Eliasson B, Franz\u00e9n S, Miftaraj M, Svensson A-M, Andersson Sundell K. Risk of cardiovascular event and mortality in relation to refill and guideline adherence to lipid-lowering medications among patients with type 2 diabetes mellitus in Sweden. BMJ Open Diabetes Res Care. 2019;7:e000639. https:\/\/doi.org\/10.1136\/bmjdrc-2018-000639.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"14428_CR18","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s13300-021-01024-y","volume":"12","author":"M Gabler","year":"2021","unstructured":"Gabler M, Picker N, Geier S, Ley L, Aberle J, Lehrke M, et al. Guideline adherence and associated outcomes in the treatment of type 2 diabetes mellitus patients with an incident cardiovascular comorbidity: an analysis based on a large german claims dataset. Diabetes Ther. 2021;12:1209\u201326. https:\/\/doi.org\/10.1007\/s13300-021-01024-y.","journal-title":"Diabetes Ther"},{"key":"14428_CR19","doi-asserted-by":"publisher","first-page":"adv00309","DOI":"10.2340\/00015555-3655","volume":"100","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder S, Ketz M, Kossack N, Akumo D, Pignot M, Gabriel S, Chavda R. Epidemiology of prurigo nodularis compared with psoriasis in Germany: a claims database analysis. Acta Derm Venereol. 2020;100:adv00309. https:\/\/doi.org\/10.2340\/00015555-3655.","journal-title":"Acta Derm Venereol"},{"key":"14428_CR20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40266-013-0074-z","volume":"30","author":"ELP Sattler","year":"2013","unstructured":"Sattler ELP, Lee JS, Perri M. Medication (re)fill adherence measures derived from pharmacy claims data in older Americans: a review of the literature. Drugs Aging. 2013;30:383\u201399. https:\/\/doi.org\/10.1007\/s40266-013-0074-z.","journal-title":"Drugs Aging"},{"key":"14428_CR21","unstructured":"Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Typ-2-Diabetes \u2013 Langfassung. 1. Auflage. Version 4. 2014. Available from: https:\/\/www.leitlinien.de\/themen\/diabetes\/archiv\/pdf\/therapie-des-typ-2-diabetes\/dm-therapie-1aufl-vers4-lang.pdf. Accessed 4 Apr 2023."},{"key":"14428_CR22","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s00125-018-4729-5","volume":"61","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61:2461\u201398. https:\/\/doi.org\/10.1007\/s00125-018-4729-5.","journal-title":"Diabetologia"},{"key":"14428_CR23","unstructured":"Hamann GF, Sander D, R\u00f6ther J, Grau A, et al. Deutsche Schlaganfall-Gesellschaft, Deutsche Gesellschaft f\u00fcr Neurologie. S3-Leitlinie \u2013 Teil 1: Sekund\u00e4rprophylaxe isch\u00e4mischer Schlaganfall und transitorische isch\u00e4mische Attacke. Version 1. 2015. https:\/\/www.awmf.org. Accessed 4 Apr 2023."},{"key":"14428_CR24","unstructured":"ESC Pocket Guidelines: Therapie des akuten Herzinfarktes bei Patienten mit ST-Streckenhebung (STEMI). Kurzfassung der ESC Guidelines for the Management of Acute Myocardial Infarction in Patients presenting with ST-segment Elevation. Version 2017."},{"key":"14428_CR25","unstructured":"Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz \u2013 Langfassung. 2. Auflage. Version 3. 2018. Available from: https:\/\/www.leitlinien.de\/themen\/herzinsuffizienz\/archiv\/pdf\/herzinsuffizienz-2aufl-vers3-lang.pdf. Accessed 4 Apr 2023."},{"key":"14428_CR26","unstructured":"Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische KHK \u2013 Langfassung. 4. Auflage. Version 1. 2016. https:\/\/www.leitlinien.de\/themen\/khk\/archiv\/pdf\/khk-4aufl-vers1-lang-2.pdf"},{"key":"14428_CR27","unstructured":"ESC Pocket Guidelines: Akutes Koronarsyndrom ohne ST-Hebung (NSTE-ACS). Kurzfassung der ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-segment Elevation. Version 2015. https:\/\/leitlinien.dgk.org\/files\/18_2015_pocket_leitlinien_nste_acs.pdf. Accessed 4 Apr 2023."},{"key":"14428_CR28","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1080\/03007995.2022.2125259","volume":"38","author":"A King","year":"2022","unstructured":"King A, Rajpura J, Liang Y, Paprocki Y, Uzoigwe C. Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease. Curr Med Res Opin. 2022;38:1831\u201340. https:\/\/doi.org\/10.1080\/03007995.2022.2125259.","journal-title":"Curr Med Res Opin"},{"key":"14428_CR29","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1080\/03007995.2020.1832455","volume":"36","author":"C Nguyen","year":"2020","unstructured":"Nguyen C, Luthra R, Kuti E, Willey VJ. Assessing risk of future cardiovascular events, healthcare resource utilization and costs in patients with type 2 diabetes, prior cardiovascular disease and both. Curr Med Res Opin. 2020;36:1927\u201338. https:\/\/doi.org\/10.1080\/03007995.2020.1832455.","journal-title":"Curr Med Res Opin"},{"key":"14428_CR30","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.37765\/ajmc.2020.43491","volume":"26","author":"S Annavarapu","year":"2020","unstructured":"Annavarapu S, Ghosh S, Li Y, Moretz C, Shetty S, Prewitt T. Health care resource utilization among patients with T2D and cardiovascular-, heart failure-, or renal-related hospitalizations. Am J Manag Care. 2020;26:e166\u201371. https:\/\/doi.org\/10.37765\/ajmc.2020.43491.","journal-title":"Am J Manag Care"},{"key":"14428_CR31","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/03007995.2018.1434497","volume":"34","author":"AD Coutinho","year":"2018","unstructured":"Coutinho AD, Raju AD, Wang W, Stafkey-Mailey D, Shetty S, Sander SD. Incremental burden of type 2 diabetes in patients experiencing cardiovascular hospitalizations. Curr Med Res Opin. 2018;34:1005\u201312. https:\/\/doi.org\/10.1080\/03007995.2018.1434497.","journal-title":"Curr Med Res Opin"},{"key":"14428_CR32","unstructured":"Br\u00fcne M, Linnenkamp U, Icks A. Gesundheits\u00f6konomische Aspekte des Diabetes mellitus. In: Deutscher Gesundheitsbericht Diabetes 2023. p. 233\u2013240."},{"key":"14428_CR33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.5603\/CJ.a2014.0067","volume":"22","author":"W Le\u015bniak","year":"2015","unstructured":"Le\u015bniak W, Ba\u0142a MM, P\u0142aczkiewicz-Jankowska E, Top\u00f3r-M\u0105dry R, Jankowski M, Sieradzki J, Banasiak W. Cardiovascular risk management in type 2 diabetes of more than 10-year duration: Results of Polish ARETAEUS2-Grupa Study. Cardiol J. 2015;22:150\u20139. https:\/\/doi.org\/10.5603\/CJ.a2014.0067.","journal-title":"Cardiol J"},{"key":"14428_CR34","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1177\/0272989X14565821","volume":"35","author":"P McEwan","year":"2015","unstructured":"McEwan P, Gordon J, Evans M, Ward T, Bennett H, Bergenheim K. Estimating cost-effectiveness in type 2 diabetes: the impact of treatment guidelines and therapy duration. Med Decis making: Int J Soc Med Decis Mak. 2015;35:660\u201370. https:\/\/doi.org\/10.1177\/0272989X14565821.","journal-title":"Med Decis making: Int J Soc Med Decis Mak"},{"key":"14428_CR35","unstructured":"Seidel-Jacobs E, T\u00f6nnies T, Rathmann W. Epidemiologie des Diabetes in Deutschland. In: Deutscher Gesundheitsbericht Diabetes 2023. pp. 10\u201315."},{"key":"14428_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2147\/VHRM.S29915","volume":"8","author":"RE Schmieder","year":"2012","unstructured":"Schmieder RE, Goebel M, Bramlage P. Barriers to cardiovascular risk prevention and management in Germany\u2013an analysis of the EURIKA study. Vasc Health Risk Manag. 2012;8:177\u201386. https:\/\/doi.org\/10.2147\/VHRM.S29915.","journal-title":"Vasc Health Risk Manag"},{"key":"14428_CR37","doi-asserted-by":"publisher","first-page":"e001626","DOI":"10.1136\/bmjsem-2023-001626","volume":"9","author":"JM Steinacker","year":"2023","unstructured":"Steinacker JM, van Mechelen W, Bloch W, B\u00f6rjesson M, Casasco M, Wolfarth B, et al. Global Alliance for the Promotion of Physical Activity: the Hamburg Declaration. BMJ Open Sport Exerc Med. 2023;9:e001626. https:\/\/doi.org\/10.1136\/bmjsem-2023-001626.","journal-title":"BMJ Open Sport Exerc Med"},{"key":"14428_CR38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1185\/03007990903396469","volume":"26","author":"EQ Wu","year":"2010","unstructured":"Wu EQ, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A, et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin. 2010;26:61\u20139. https:\/\/doi.org\/10.1185\/03007990903396469.","journal-title":"Curr Med Res Opin"},{"key":"14428_CR39","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.jaip.2023.12.049","volume":"12","author":"JFM van Boven","year":"2024","unstructured":"van Boven JFM, Lavorini F, Agh T, Sadatsafavi M, Patino O, Muresan B. Cost-effectiveness and impact on health care utilization of interventions to improve medication adherence and outcomes in asthma and chronic obstructive pulmonary disease: a systematic literature review. J Allergy Clin Immunol Pract. 2024;12:1228\u201343. https:\/\/doi.org\/10.1016\/j.jaip.2023.12.049.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"14428_CR40","doi-asserted-by":"publisher","first-page":"e037357","DOI":"10.1161\/JAHA.124.037357","volume":"13","author":"JS Lee","year":"2024","unstructured":"Lee JS, Segura Escano R, Therrien NL, Kumar A, Bhatt A, Pollack LM, et al. Antihypertensive medication adherence and medical costs, health care use, and labor productivity among people with hypertension. J Am Heart Assoc. 2024;13:e037357. https:\/\/doi.org\/10.1161\/JAHA.124.037357.","journal-title":"J Am Heart Assoc"},{"key":"14428_CR41","doi-asserted-by":"publisher","unstructured":"Swart E, Gothe H, Geyer S, Jaunzeme J, Maier B, Grobe TG, Ihle P. Gute Praxis Sekund\u00e4rdatenanalyse (GPS): Leitlinien und Empfehlungen. [Good Practice of Secondary Data Analysis (GPS): guidelines and recommendations]. Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)). 2015;77:120\u20136. https:\/\/doi.org\/10.1055\/s-0034-1396815","DOI":"10.1055\/s-0034-1396815"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-14428-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14428-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14428-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:00:16Z","timestamp":1777392016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-14428-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14428"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-14428-y","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"1 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study complied with relevant European and German data protection regulations. All patient-level data in the database were anonymized. No direct contact with patients or primary collection of individual human patient data occurred and, thus, no informed consent was required. In line with the respective national good practice guidelines, no approval of an ethics committee was required for this analysis of secondary data [\n                      \n                      ].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"JA received honoraria for scientific cooperation, advisory boards, or speakers bureau of any of the following: Astra Zeneca, Bayer, Boehringer Ingelheim, Lilly, Novartis, Novo Nordisk, and rhythm pharmaceuticalsDD has received speaker\u2019s honoraria from Bayer Healthcare, AOP Health, AstraZeneca, Pfizer, Daiichi Sankyo, Boston Scientific and consulting fees from Daiichi Sankyo, Boston Scientific, CSL Behring, and Janssen.ML received grants and personal fees from Boehringer Ingelheim, MSD, Novo Nordisk and personal fees from Amgen, Sanofi, Astra Zeneca, Bayer, Lilly, Daiichi Sankyo, Novartis, Amarin, Abiomed, BMS, and Pfizer.MGr received speaker\u2019s honoraria and honoraria for advisory boards from Boehringer Ingelheim, Bayer vital, Pfizer, AstraZeneca, Novo Nordisc, iRhythm, Alexion and streamed-up.SM received grants from Fractly and Almased, speaker\u2019s honoraria from Astra Zeneca, Lilly, Boehringer Ingelheim, StreamedUp, MedUpdate, Bayer, and Marpinion, and consultant fees from AXA Versicherung, Generali Versicherung, Fractly, Almased, Boehringer Ingelheim, Bionorica, and gbo Ger\u00e4tebau.MS is an employee of Berlin Center for Epidemiology and Health Research (ZEG) at the time of the study, which was contracted by Boehringer Ingelheim to conduct this study.NK and LR are employees of Scientific Institute for Health Economics and Health System Research (WIG2) at the time of the study, which was contracted by Boehringer Ingelheim to conduct this study.MGa and SOT are employees of Boehringer Ingelheim.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"600"}}